Back to resultsA Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Primary Purpose
Urinary Tract Cancer
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Atezolizumab
Sponsored by
About this trial
This is an interventional treatment trial for Urinary Tract Cancer
Eligibility Criteria
Inclusion Criteria:
- Participants with histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract
- Participants with measurable and/or non-measurable disease according to RECIST v1.1
- Participants must have progressed during or following treatment with at least one prior (and not more than 3) treatments for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
- If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen block should be submitted
- Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2
Exclusion Criteria:
- Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation
- Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible
- Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible
- Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
- Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
- Significant renal disorder indicating a need for renal transplant
Sites / Locations
- Inst. Alexander Fleming; Oncologia
- Hospital Aleman
- Hospital Britanico de Buenos Aires
- Canberra Hospital; Medical Oncology
- Macquarie University Hospital
- Prince of Wales Hospital; Oncology
- Northern Cancer Institute
- Calvary Mater Newcastle; Medical Oncology
- Icon Cancer Foundation
- Royal Adelaide Hospital
- Royal Hobart Hospital; Hematology/Oncology
- Box Hill Hospital
- Austin Hospital Olivia Newton John Cancer Centre
- Medizinische Universität Innsbruck; Universitätsklinik für Urologie
- Ordensklinikum Linz Elisabethinen; Abteilung für Urologie und Andrologie
- Landeskrankenhaus Salzburg; Universitätsklinik für Urologie und Andrologie der PMU
- Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
- Medizinische Universität Wien; Universitätsklinik für Urologie
- UZ Brussel
- Cliniques Universitaires St-Luc
- UZ Leuven Gasthuisberg
- CHU Sart-Tilman
- Pronutrir - suporte nutricional e quimioterapia ltda.
- Centro Integrado de Oncologia de Curitiba
- Hospital Sao Lucas - PUCRS
- Hospital de Cancer de Barretos
- Hospital Sírio-Libanês
- Hospital Alemao Oswaldo Cruz
- Complex Oncology Center (COC)-Plovidiv
- University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
- SHATOD - Sofia
- Tom Baker Cancer Centre-Calgary
- Cross Cancer Institute ; Dept of Medical Oncology
- Queen Elizabeth II Health Sciences Centre
- Royal Victoria Hospital
- The Ottawa Hospital Cancer Center; General Campus
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
- Clinica del Country
- Clinical Hospital Centre Zagreb
- Fakultni nemocnice u sv. Anny v Brne
- Fakultni nemocnice Kralovske Vinohrady
- Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni
- Aalborg Universitetshospital; Klinik Kirurgi-Kræft, Onkologisk afd.
- Aarhus Universitetshospital; Kræftafdelingen
- Herlev Hospital; Afdeling for Kræftbehandling
- Rigshospitalet; Onkologisk Klinik
- East Tallinn Central Hospital; Clinic of Internal Medicine
- North Estonia Medical Centre Foundation; Oncology Center
- Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik für Urologie
- Universitätsklinikum Erlangen; Medizinische Klinik 5; Hämatologie und Internistische Onkologie
- Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Urologie
- Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie
- Medizinische Hochschule Hannover; Klinik für Urologie und Onkologische Urologie
- Onkologische Schwerpunktpraxis
- Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Urologie
- Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus
- Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik
- Universitätsklinikum Münster, Klinik für Urologie und Kinderurologie
- Universitätsklinikum Tübingen; Klinik für Urologie
- Universitätsklinikum Ulm; Klinik für Urologie
- Alexandras General Hospital of Athens; Oncology Department
- IASO General Hospital of Athens
- Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept.
- Metropolitan Hospital; 2Nd Oncology Clinic
- Thermi Clinic; Oncology Clinic
- Euromedical General Clinic of Thessaloniki; Oncology Department
- Papageorgiou General Hospital; Medical Oncology
- Honvédelmi Minisztérium Állami Egészségügyi Központ; Onkológiai Osztály; Oncology department
- Semmelwies University of Medicine; Urology Dept.
- Orszagos Onkologiai Intezet
- Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
- Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
- HealthCare Global Cancer Centre; Medical Oncology
- TATA Medical Centre; Medical Oncology
- Artemis Health Institute
- Max Super Speciality Hospital
- Cork University Hospital
- Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit
- Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica
- Azienda Ospedaliera Universitaria Federico II
- ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico
- AZ.Osp S. Orsola - Malpighi-Reparto di Oncologia Medica
- IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
- A.O. Universitaria Policlinico Di Modena; Oncologia
- Arcispedale Santa Maria Nuova; Oncologia
- A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia
- Policlinico Universitario Campus Biomedico Di Roma; U.O.Oncologia Medica
- Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica
- Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica
- IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
- Asst Papa Giovanni XXIII; Oncologia Medica
- ASST DI CREMONA; Dip. Medicina - S.C. Oncologia
- Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
- Istituto Europeo Di Oncologia
- A.O. UNIVERSITARIA S. LUIGI GONZAGA; Oncologia Medica
- Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
- IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia
- A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia
- Ospedale Cannizzaro, Oncologia
- Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia
- Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2
- Azienda Ospedaliera S. Maria - Terni; Oncologia
- IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima
- Azienda Ospedaliera di Verona-Policlinico G.B. Rossi; Oncologia Medica
- Hotel Dieu de France; Oncology
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics - Endocrinology clinic
- National Cancer Institute
- NKI/AvL
- VU MEDISCH CENTRUM; Dept. of Medical Oncology
- Academ Ziekenhuis Groningen; Medical Oncology
- Maastricht University Medical Centre; Medical Oncology
- St. Antonius locatie Leidsche Rijn
- Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii
- Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego
- Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o.
- NZOZ Onko-Dent G. L. Slomian, Spolka Jawna
- Hospital de Braga; Servico de Oncologia Medica X
- HUC; Servico de Urologia e Transplantacao Renal
- Hospital de Santa Maria; Servico de Oncologia Medica
- IPO do Porto; Servico de Oncologia Medica
- Oncopremium Team Srl
- Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Spital de zi-Parter
- Centrul de Oncologie Sfantul Nectarie
- Centrul de Radioterapie AMETHYST
- Oncomed SRL; Oncologie
- Blokhin Cancer Research Center; Urological Dept
- P.A. Herzen Oncological Inst. ; Oncology
- King Faisal Specialist Hospital & Research Centre; Oncology
- Narodny onkologicky ustav
- Hospital Univ. Central de Asturias; Servicio de Oncologia
- Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
- Complejo Hospitalario de Althaia; Servicio de Oncologia
- Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
- Hospital Universitario Reina Sofia; Servicio de Oncologia
- Hospital Universitario Son Espases; Servicio de Oncologia
- Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
- Hospital Universitario de Canarias;servicio de Oncologia
- Hospital de Basurto; Servicio de Oncologia
- Hospital del Mar Barcelona
- Hospital Univ Vall d'Hebron; Servicio de Oncologia
- Hospital Clínic i Provincial; Servicio de Oncología
- Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
- Hospital Duran i Reynals; Oncologia
- Hospital San Pedro De Alcantara; Servicio de Oncologia
- Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia
- Hospital General Universitario de Guadalajara; Servicio de Oncologia
- Hospital Lucus Augusti; Servicio de Oncologia
- Hospital Ramon y Cajal; Servicio de Oncologia
- Hospital Clinico San Carlos; Servicio de Oncologia
- Hospital Universitario 12 de Octubre; Servicio de Oncologia
- Hospital Universitario La Paz; Servicio de Oncologia
- HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
- Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
- Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia
- Hospital de Navarra; Servicio de Oncologia
- Complejo Hospitalario de Orense; Servicio de Oncologia
- Hospital Universitario Virgen del Rocio; Servicio de Oncologia
- Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia
- Hospital Clínico Universitario de Valencia; Servicio de Oncología
- Hospital General Universitario de Valencia; Servicio de oncologia
- Hospital La Fe
- Ospedale Regionale di Bellinzona Medizin Onkologie
- Universitaetsspital Basel; Onkologie
- Inselspital Bern; Universitätsklinik für medizinische Onkologie
- Kantonsspital Graubünden Medizin Onkologie; Onkologie und Hämatologie
- Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie
- Luzerner Kantonsspital; Medizinische Onkologie
- Kantonsspital Winterthur; Medizinische Onkologie
- National Cheng Kung Uni Hospital; Dept of Hematology and Oncology
- Chang Gung Medical Foundation-Linkou, Urinary Oncology
- Velindre Cancer Centre
- Raigmore Hospital; Dept of Radiotherapy & Oncology
- Leicester Royal Infirmary NHS Trust
- Barts and the London NHS Trust.
- Royal Marsden NHS Foundation Trust
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Atezolizumab
Arm Description
Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
Outcomes
Primary Outcome Measures
Percentage of Participants With Adverse Events
Secondary Outcome Measures
Overall Survival (OS)
Progression Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
PFS as per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST)
Percentage of Participants With Best Overall Response as Assessed by RECIST v1.1
Percentage of Participants With Best Overall Response as Assessed by Modified RECIST
Percentage of Participants With Disease Control as Assessed by RECIST v1.1
Percentage of Participants With Disease Control as Assessed by Modified RECIST
Duration of Response as Assessed by RECIST v1.1
Duration of Response as Assessed by Modified RECIST
Change From Baseline in Health-Related Quality of Life (HRQoL), as Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score
Change from Baseline in European Quality of Life (EuroQoL) Group 5-Dimension 5-Level (EQ-5D-5L) Self Report Questionnaire Health Utility Score
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02928406
Brief Title
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Official Title
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
November 30, 2016 (Actual)
Primary Completion Date
December 12, 2022 (Actual)
Study Completion Date
December 12, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1005 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Atezolizumab
Arm Type
Experimental
Arm Description
Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
Intervention Type
Drug
Intervention Name(s)
Atezolizumab
Other Intervention Name(s)
MPDL3280A
Intervention Description
Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
Primary Outcome Measure Information:
Title
Percentage of Participants With Adverse Events
Time Frame
Baseline up to end of study (up to approximately 6 years)
Secondary Outcome Measure Information:
Title
Overall Survival (OS)
Time Frame
Randomization until death from any cause (up to approximately 6 years)
Title
Progression Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Time Frame
Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Title
PFS as per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST)
Time Frame
Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Title
Percentage of Participants With Best Overall Response as Assessed by RECIST v1.1
Time Frame
Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Title
Percentage of Participants With Best Overall Response as Assessed by Modified RECIST
Time Frame
Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Title
Percentage of Participants With Disease Control as Assessed by RECIST v1.1
Time Frame
Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Title
Percentage of Participants With Disease Control as Assessed by Modified RECIST
Time Frame
Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Title
Duration of Response as Assessed by RECIST v1.1
Time Frame
Time from first occurrence of a documented response to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Title
Duration of Response as Assessed by Modified RECIST
Time Frame
Time from first occurrence of a documented response to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
Title
Change From Baseline in Health-Related Quality of Life (HRQoL), as Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score
Time Frame
Baseline, Day 1 of Cycles 1, 2, 3 and thereafter every 9 weeks for 54 weeks from study treatment start; and then every 12 weeks until progression/study discontinuation (up to approximately 6 years) (Cycle length = 21 days)
Title
Change from Baseline in European Quality of Life (EuroQoL) Group 5-Dimension 5-Level (EQ-5D-5L) Self Report Questionnaire Health Utility Score
Time Frame
Baseline, Day 1 of Cycles 1, 2, 3 and thereafter every 9 weeks for 54 weeks from study treatment start; and then every 12 weeks until progression/study discontinuation (up to approximately 6 years) (Cycle length = 21 days)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participants with histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract
Participants with measurable and/or non-measurable disease according to RECIST v1.1
Participants must have progressed during or following treatment with at least one prior (and not more than 3) treatments for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen block should be submitted
Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2
Exclusion Criteria:
Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation
Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible
Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible
Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
Significant renal disorder indicating a need for renal transplant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
Inst. Alexander Fleming; Oncologia
City
Buenos Aires
ZIP/Postal Code
C1426ANZ
Country
Argentina
Facility Name
Hospital Aleman
City
Caba
ZIP/Postal Code
C1118AAT
Country
Argentina
Facility Name
Hospital Britanico de Buenos Aires
City
Ciudad Autonoma Buenos Aires
ZIP/Postal Code
C1284AEB
Country
Argentina
Facility Name
Canberra Hospital; Medical Oncology
City
Canberra
State/Province
Australian Capital Territory
ZIP/Postal Code
2606
Country
Australia
Facility Name
Macquarie University Hospital
City
Macquarie Park
State/Province
New South Wales
ZIP/Postal Code
2109
Country
Australia
Facility Name
Prince of Wales Hospital; Oncology
City
Randwick
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Facility Name
Northern Cancer Institute
City
St Leonards
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Facility Name
Calvary Mater Newcastle; Medical Oncology
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2298
Country
Australia
Facility Name
Icon Cancer Foundation
City
South Brisbane
State/Province
Queensland
ZIP/Postal Code
4101
Country
Australia
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Royal Hobart Hospital; Hematology/Oncology
City
Hobart
State/Province
Tasmania
ZIP/Postal Code
7000
Country
Australia
Facility Name
Box Hill Hospital
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Austin Hospital Olivia Newton John Cancer Centre
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Facility Name
Medizinische Universität Innsbruck; Universitätsklinik für Urologie
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Ordensklinikum Linz Elisabethinen; Abteilung für Urologie und Andrologie
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
Landeskrankenhaus Salzburg; Universitätsklinik für Urologie und Andrologie der PMU
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Facility Name
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
Medizinische Universität Wien; Universitätsklinik für Urologie
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
UZ Brussel
City
Brussel
ZIP/Postal Code
1090
Country
Belgium
Facility Name
Cliniques Universitaires St-Luc
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
UZ Leuven Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
CHU Sart-Tilman
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Pronutrir - suporte nutricional e quimioterapia ltda.
City
Fortaleza
State/Province
CE
ZIP/Postal Code
60810-180
Country
Brazil
Facility Name
Centro Integrado de Oncologia de Curitiba
City
Curitiba
State/Province
PR
ZIP/Postal Code
80810-050
Country
Brazil
Facility Name
Hospital Sao Lucas - PUCRS
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Hospital de Cancer de Barretos
City
Barretos
State/Province
SP
ZIP/Postal Code
14784-400
Country
Brazil
Facility Name
Hospital Sírio-Libanês
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01308-050
Country
Brazil
Facility Name
Hospital Alemao Oswaldo Cruz
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01323-903
Country
Brazil
Facility Name
Complex Oncology Center (COC)-Plovidiv
City
Plovdiv
ZIP/Postal Code
4000
Country
Bulgaria
Facility Name
University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
City
Sofia
ZIP/Postal Code
1527
Country
Bulgaria
Facility Name
SHATOD - Sofia
City
Sofia
ZIP/Postal Code
1784
Country
Bulgaria
Facility Name
Tom Baker Cancer Centre-Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N2
Country
Canada
Facility Name
Cross Cancer Institute ; Dept of Medical Oncology
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Facility Name
Queen Elizabeth II Health Sciences Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 2Y9
Country
Canada
Facility Name
Royal Victoria Hospital
City
Barrie
State/Province
Ontario
ZIP/Postal Code
L4M 6M2
Country
Canada
Facility Name
The Ottawa Hospital Cancer Center; General Campus
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 1C4
Country
Canada
Facility Name
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
City
Nanjing City
ZIP/Postal Code
210008
Country
China
Facility Name
Clinica del Country
City
Bogota
ZIP/Postal Code
11001
Country
Colombia
Facility Name
Clinical Hospital Centre Zagreb
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Fakultni nemocnice u sv. Anny v Brne
City
Brno
ZIP/Postal Code
656 91
Country
Czechia
Facility Name
Fakultni nemocnice Kralovske Vinohrady
City
Praha
ZIP/Postal Code
100 34
Country
Czechia
Facility Name
Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni
City
Praha
ZIP/Postal Code
140 59
Country
Czechia
Facility Name
Aalborg Universitetshospital; Klinik Kirurgi-Kræft, Onkologisk afd.
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Facility Name
Aarhus Universitetshospital; Kræftafdelingen
City
Aarhus N
ZIP/Postal Code
8200
Country
Denmark
Facility Name
Herlev Hospital; Afdeling for Kræftbehandling
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Facility Name
Rigshospitalet; Onkologisk Klinik
City
København Ø
ZIP/Postal Code
2100
Country
Denmark
Facility Name
East Tallinn Central Hospital; Clinic of Internal Medicine
City
Tallinn
ZIP/Postal Code
11312
Country
Estonia
Facility Name
North Estonia Medical Centre Foundation; Oncology Center
City
Tallinn
ZIP/Postal Code
13419
Country
Estonia
Facility Name
Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik für Urologie
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Universitätsklinikum Erlangen; Medizinische Klinik 5; Hämatologie und Internistische Onkologie
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Urologie
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie
City
Halle (Saale)
ZIP/Postal Code
06120
Country
Germany
Facility Name
Medizinische Hochschule Hannover; Klinik für Urologie und Onkologische Urologie
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Onkologische Schwerpunktpraxis
City
Heidelberg
ZIP/Postal Code
69115
Country
Germany
Facility Name
Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Urologie
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus
City
Mönchengladbach
ZIP/Postal Code
41063
Country
Germany
Facility Name
Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik
City
München
ZIP/Postal Code
81675
Country
Germany
Facility Name
Universitätsklinikum Münster, Klinik für Urologie und Kinderurologie
City
Münster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Universitätsklinikum Tübingen; Klinik für Urologie
City
Tübingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
Universitätsklinikum Ulm; Klinik für Urologie
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
Alexandras General Hospital of Athens; Oncology Department
City
Athens
ZIP/Postal Code
115 28
Country
Greece
Facility Name
IASO General Hospital of Athens
City
Athens
ZIP/Postal Code
155 62
Country
Greece
Facility Name
Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept.
City
Kifisia
ZIP/Postal Code
145 64
Country
Greece
Facility Name
Metropolitan Hospital; 2Nd Oncology Clinic
City
Piraeus
ZIP/Postal Code
185 47
Country
Greece
Facility Name
Thermi Clinic; Oncology Clinic
City
Thermi Thessalonikis
ZIP/Postal Code
570 01
Country
Greece
Facility Name
Euromedical General Clinic of Thessaloniki; Oncology Department
City
Thessaloniki
ZIP/Postal Code
546 45
Country
Greece
Facility Name
Papageorgiou General Hospital; Medical Oncology
City
Thessaloniki
ZIP/Postal Code
564 29
Country
Greece
Facility Name
Honvédelmi Minisztérium Állami Egészségügyi Központ; Onkológiai Osztály; Oncology department
City
Budapest
ZIP/Postal Code
1062
Country
Hungary
Facility Name
Semmelwies University of Medicine; Urology Dept.
City
Budapest
ZIP/Postal Code
1082
Country
Hungary
Facility Name
Orszagos Onkologiai Intezet
City
Budapest
ZIP/Postal Code
1122
Country
Hungary
Facility Name
Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
City
Szeged
ZIP/Postal Code
6720
Country
Hungary
Facility Name
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
City
Szolnok
ZIP/Postal Code
5004
Country
Hungary
Facility Name
HealthCare Global Cancer Centre; Medical Oncology
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380060
Country
India
Facility Name
TATA Medical Centre; Medical Oncology
City
Kolkata
State/Province
WEST Bengal
ZIP/Postal Code
700156
Country
India
Facility Name
Artemis Health Institute
City
Gurgaon
ZIP/Postal Code
122001
Country
India
Facility Name
Max Super Speciality Hospital
City
New Delhi
ZIP/Postal Code
110017
Country
India
Facility Name
Cork University Hospital
City
Cork
Country
Ireland
Facility Name
Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit
City
Dublin
ZIP/Postal Code
24
Country
Ireland
Facility Name
Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica
City
Chieti
State/Province
Abruzzo
ZIP/Postal Code
66100
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Federico II
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Facility Name
ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Facility Name
AZ.Osp S. Orsola - Malpighi-Reparto di Oncologia Medica
City
Bologna
State/Province
Emilia-Romagna
ZIP/Postal Code
40138
Country
Italy
Facility Name
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
City
Meldola
State/Province
Emilia-Romagna
ZIP/Postal Code
47014
Country
Italy
Facility Name
A.O. Universitaria Policlinico Di Modena; Oncologia
City
Modena
State/Province
Emilia-Romagna
ZIP/Postal Code
41100
Country
Italy
Facility Name
Arcispedale Santa Maria Nuova; Oncologia
City
Reggio Emilia
State/Province
Emilia-Romagna
ZIP/Postal Code
42100
Country
Italy
Facility Name
A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia
City
Udine
State/Province
Friuli-Venezia Giulia
ZIP/Postal Code
33100
Country
Italy
Facility Name
Policlinico Universitario Campus Biomedico Di Roma; U.O.Oncologia Medica
City
Roma
State/Province
Lazio
ZIP/Postal Code
00128
Country
Italy
Facility Name
Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica
City
Roma
State/Province
Lazio
ZIP/Postal Code
00152
Country
Italy
Facility Name
Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica
City
Roma
State/Province
Lazio
ZIP/Postal Code
00168
Country
Italy
Facility Name
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
City
Genova
State/Province
Liguria
ZIP/Postal Code
16132
Country
Italy
Facility Name
Asst Papa Giovanni XXIII; Oncologia Medica
City
Bergamo
State/Province
Lombardia
ZIP/Postal Code
24127
Country
Italy
Facility Name
ASST DI CREMONA; Dip. Medicina - S.C. Oncologia
City
Cremona
State/Province
Lombardia
ZIP/Postal Code
26100
Country
Italy
Facility Name
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Facility Name
Istituto Europeo Di Oncologia
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20141
Country
Italy
Facility Name
A.O. UNIVERSITARIA S. LUIGI GONZAGA; Oncologia Medica
City
Orbassano
State/Province
Piemonte
ZIP/Postal Code
10043
Country
Italy
Facility Name
Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
City
Bari
State/Province
Puglia
ZIP/Postal Code
70124
Country
Italy
Facility Name
IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia
City
San Giovanni Rotondo
State/Province
Puglia
ZIP/Postal Code
71013
Country
Italy
Facility Name
A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia
City
Cagliari
State/Province
Sardegna
ZIP/Postal Code
09100
Country
Italy
Facility Name
Ospedale Cannizzaro, Oncologia
City
Catania
State/Province
Sicilia
ZIP/Postal Code
95126
Country
Italy
Facility Name
Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia
City
Arezzo
State/Province
Toscana
ZIP/Postal Code
52100
Country
Italy
Facility Name
Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2
City
Pisa
State/Province
Toscana
ZIP/Postal Code
56100
Country
Italy
Facility Name
Azienda Ospedaliera S. Maria - Terni; Oncologia
City
Terni
State/Province
Umbria
ZIP/Postal Code
05100
Country
Italy
Facility Name
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima
City
Padova
State/Province
Veneto
ZIP/Postal Code
35128
Country
Italy
Facility Name
Azienda Ospedaliera di Verona-Policlinico G.B. Rossi; Oncologia Medica
City
Verona
State/Province
Veneto
ZIP/Postal Code
37134
Country
Italy
Facility Name
Hotel Dieu de France; Oncology
City
Beirut
ZIP/Postal Code
2063 1111
Country
Lebanon
Facility Name
Hospital of Lithuanian University of Health Sciences Kaunas Clinics - Endocrinology clinic
City
Kaunas
ZIP/Postal Code
50009
Country
Lithuania
Facility Name
National Cancer Institute
City
Vilnius
ZIP/Postal Code
08660
Country
Lithuania
Facility Name
NKI/AvL
City
Amsterdam
ZIP/Postal Code
1066 CX
Country
Netherlands
Facility Name
VU MEDISCH CENTRUM; Dept. of Medical Oncology
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
Facility Name
Academ Ziekenhuis Groningen; Medical Oncology
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Facility Name
Maastricht University Medical Centre; Medical Oncology
City
Maastricht
ZIP/Postal Code
6229 HX
Country
Netherlands
Facility Name
St. Antonius locatie Leidsche Rijn
City
Utrecht
ZIP/Postal Code
3543 AZ
Country
Netherlands
Facility Name
Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii
City
Lublin
ZIP/Postal Code
20-090
Country
Poland
Facility Name
Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego
City
Poznan
ZIP/Postal Code
60-570
Country
Poland
Facility Name
Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o.
City
Warszawa
ZIP/Postal Code
04-073
Country
Poland
Facility Name
NZOZ Onko-Dent G. L. Slomian, Spolka Jawna
City
Żory
ZIP/Postal Code
44-240
Country
Poland
Facility Name
Hospital de Braga; Servico de Oncologia Medica X
City
Braga
ZIP/Postal Code
4710-243
Country
Portugal
Facility Name
HUC; Servico de Urologia e Transplantacao Renal
City
Coimbra
ZIP/Postal Code
3000-075
Country
Portugal
Facility Name
Hospital de Santa Maria; Servico de Oncologia Medica
City
Lisboa
ZIP/Postal Code
1649-035
Country
Portugal
Facility Name
IPO do Porto; Servico de Oncologia Medica
City
Porto
ZIP/Postal Code
4200-072
Country
Portugal
Facility Name
Oncopremium Team Srl
City
Baia Mare
ZIP/Postal Code
430291
Country
Romania
Facility Name
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Spital de zi-Parter
City
Cluj-Napoca
ZIP/Postal Code
400015
Country
Romania
Facility Name
Centrul de Oncologie Sfantul Nectarie
City
Craiova
ZIP/Postal Code
200347
Country
Romania
Facility Name
Centrul de Radioterapie AMETHYST
City
Floresti
ZIP/Postal Code
407280
Country
Romania
Facility Name
Oncomed SRL; Oncologie
City
Timisoara
ZIP/Postal Code
300239
Country
Romania
Facility Name
Blokhin Cancer Research Center; Urological Dept
City
Moscow
ZIP/Postal Code
115478
Country
Russian Federation
Facility Name
P.A. Herzen Oncological Inst. ; Oncology
City
Moscow
ZIP/Postal Code
125284
Country
Russian Federation
Facility Name
King Faisal Specialist Hospital & Research Centre; Oncology
City
Riyadh
ZIP/Postal Code
11211
Country
Saudi Arabia
Facility Name
Narodny onkologicky ustav
City
Bratislava
ZIP/Postal Code
833 10
Country
Slovakia
Facility Name
Hospital Univ. Central de Asturias; Servicio de Oncologia
City
Oviedo
State/Province
Asturias
ZIP/Postal Code
33011
Country
Spain
Facility Name
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Complejo Hospitalario de Althaia; Servicio de Oncologia
City
Manresa
State/Province
Barcelona
ZIP/Postal Code
08243
Country
Spain
Facility Name
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
City
Sabadell
State/Province
Barcelona
ZIP/Postal Code
8208
Country
Spain
Facility Name
Hospital Universitario Reina Sofia; Servicio de Oncologia
City
Córdoba
State/Province
Cordoba
ZIP/Postal Code
14004
Country
Spain
Facility Name
Hospital Universitario Son Espases; Servicio de Oncologia
City
Palma De Mallorca
State/Province
Islas Baleares
ZIP/Postal Code
07014
Country
Spain
Facility Name
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
City
Santiago de Compostela
State/Province
LA Coruña
ZIP/Postal Code
15706
Country
Spain
Facility Name
Hospital Universitario de Canarias;servicio de Oncologia
City
La Laguna
State/Province
Tenerife
ZIP/Postal Code
38320
Country
Spain
Facility Name
Hospital de Basurto; Servicio de Oncologia
City
Bilbao
State/Province
Vizcaya
ZIP/Postal Code
48013
Country
Spain
Facility Name
Hospital del Mar Barcelona
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Hospital Univ Vall d'Hebron; Servicio de Oncologia
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Clínic i Provincial; Servicio de Oncología
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Facility Name
Hospital Duran i Reynals; Oncologia
City
Barcelona
ZIP/Postal Code
08907
Country
Spain
Facility Name
Hospital San Pedro De Alcantara; Servicio de Oncologia
City
Caceres
ZIP/Postal Code
10003
Country
Spain
Facility Name
Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
Hospital General Universitario de Guadalajara; Servicio de Oncologia
City
Guadalajara
ZIP/Postal Code
19002
Country
Spain
Facility Name
Hospital Lucus Augusti; Servicio de Oncologia
City
Lugo
ZIP/Postal Code
27003
Country
Spain
Facility Name
Hospital Ramon y Cajal; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Hospital Clinico San Carlos; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario 12 de Octubre; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital Universitario La Paz; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia
City
Murcia
ZIP/Postal Code
30008
Country
Spain
Facility Name
Hospital de Navarra; Servicio de Oncologia
City
Navarra
ZIP/Postal Code
31008
Country
Spain
Facility Name
Complejo Hospitalario de Orense; Servicio de Oncologia
City
Orense
ZIP/Postal Code
32005
Country
Spain
Facility Name
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia
City
Toledo
ZIP/Postal Code
45004
Country
Spain
Facility Name
Hospital Clínico Universitario de Valencia; Servicio de Oncología
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Facility Name
Hospital General Universitario de Valencia; Servicio de oncologia
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Facility Name
Hospital La Fe
City
Valencia
Country
Spain
Facility Name
Ospedale Regionale di Bellinzona Medizin Onkologie
City
Bellinzona
ZIP/Postal Code
6500
Country
Swaziland
Facility Name
Universitaetsspital Basel; Onkologie
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
Inselspital Bern; Universitätsklinik für medizinische Onkologie
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Facility Name
Kantonsspital Graubünden Medizin Onkologie; Onkologie und Hämatologie
City
Chur
ZIP/Postal Code
7000
Country
Switzerland
Facility Name
Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie
City
Geneve
ZIP/Postal Code
1211
Country
Switzerland
Facility Name
Luzerner Kantonsspital; Medizinische Onkologie
City
Luzern
ZIP/Postal Code
6004
Country
Switzerland
Facility Name
Kantonsspital Winterthur; Medizinische Onkologie
City
Winterthur
ZIP/Postal Code
8401
Country
Switzerland
Facility Name
National Cheng Kung Uni Hospital; Dept of Hematology and Oncology
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Facility Name
Chang Gung Medical Foundation-Linkou, Urinary Oncology
City
Taoyuan
ZIP/Postal Code
333
Country
Taiwan
Facility Name
Velindre Cancer Centre
City
Cardiff
ZIP/Postal Code
CF14 2TL
Country
United Kingdom
Facility Name
Raigmore Hospital; Dept of Radiotherapy & Oncology
City
Inverness
ZIP/Postal Code
IV1 3UJ
Country
United Kingdom
Facility Name
Leicester Royal Infirmary NHS Trust
City
Leicester
ZIP/Postal Code
LE1 5WW
Country
United Kingdom
Facility Name
Barts and the London NHS Trust.
City
London
ZIP/Postal Code
EC1A 7BE
Country
United Kingdom
Facility Name
Royal Marsden NHS Foundation Trust
City
Sutton
ZIP/Postal Code
SM2 5PT
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
33984672
Citation
Bamias A, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabro F, Kramer M, de Velasco G, Zakopoulou R, Tzannis K, Sternberg CN. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. ESMO Open. 2021 Jun;6(3):100152. doi: 10.1016/j.esmoop.2021.100152. Epub 2021 May 10.
Results Reference
derived
PubMed Identifier
33835866
Citation
Merseburger AS, Castellano D, Powles T, Loriot Y, Retz M, Voortman J, Huddart RA, Gedye C, Van Der Heijden MS, Gurney H, Ong M, de Ducla S, Pavlova J, Fear S, Sternberg CN. Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. J Urol. 2021 Aug;206(2):240-251. doi: 10.1097/JU.0000000000001768. Epub 2021 Apr 9.
Results Reference
derived
PubMed Identifier
32905959
Citation
Loriot Y, Sternberg CN, Castellano D, Oosting SF, Dumez H, Huddart R, Vianna K, Alonso Gordoa T, Skoneczna I, Fay AP, Nole F, Massari F, Brasiuniene B, Maroto P, Fear S, Di Nucci F, de Ducla S, Choy E. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. Eur J Cancer. 2020 Oct;138:202-211. doi: 10.1016/j.ejca.2020.07.023. Epub 2020 Sep 6.
Results Reference
derived
PubMed Identifier
32399958
Citation
Cathomas R, Schardt J, Pless M, Llado A, Mach N, Riklin C, Haefeli J, Fear S, Stenner F. Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice. Swiss Med Wkly. 2020 May 4;150:w20223. doi: 10.4414/smw.2020.20223. eCollection 2020 May 4.
Results Reference
derived
PubMed Identifier
30910346
Citation
Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.
Results Reference
derived
Learn more about this trial
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
We'll reach out to this number within 24 hrs